The patient is waiting

Every day, along with our partners, we move closer to our goal of applying science to deliver breakthrough medicines to patients around the world. From innovation to validation to commercialization, we continue to seek new partners who can help us achieve our goal.

Introduction

Agenus is focused in the areas of oncology and infectious diseases. With our strong platform technologies, we have advanced multiple product candidates through the clinic and defined the most suitable patient populations to benefit from our novel vaccine approach. To advance our pioneering work in HSP-based vaccines, we are applying our technology to both autologous and non-autologous therapies.

Agenus' licensees for QS-21 Stimulon® adjuvant include GlaxoSmithKline, Janssen Alzheimer Immunotherapy (a wholly owned subsidiary of Johnson & Johnson), and Integrated Biotherapeutics. QS-21 represents the most advanced adjuvant currently in clinical development.

Agenus and NewVac LLC (a subsidiary of ChemRar High Tech Center and resident of the Skolkovo Innovation Center in Russia), a company focused on the development of innovative technology for cancer immunotherapy, have formed a license, development and manufacturing technology transfer agreement for Agenus’ Oncophage® (HSPPC-96 ; vitespen) vaccine. Oncophage is approved in Russia for the treatment of renal cell carcinoma ("RCC”; kidney cancer) in patients at intermediate risk of recurrence. Under the agreement, Agenus has granted NewVac an exclusive license to manufacture, market and sell Oncophage as well as pursue a development program of Oncophage in combination with NewVac’s co-adjuvant technology in the Russian Federation and CIS countries.

Our business strategy is two pronged (1) to discover, develop and commercialize novel vaccines in our core therapeutic areas and (2) to partner and collaborate with leading institutions and companies in an effort to speed our product candidates to market. We recognize the importance of combining our expertise with those of our industry colleagues to help important medical discoveries reach patients and physicians faster.

We are currently pursuing internal product development in both oncology and infectious diseases and we are actively pursuing a variety of partnership opportunities to augment our internal programs.

Key benefits of working with Agenus include:

  • Over 15 years of clinical development expertise
  • Fully integrated research and development departments
  • GMP manufacturing capabilities with experienced operations team
  • Business development & commercial experience
  • Public company infrastructure

In-Licensing

In an effort to build near-term commercial opportunities, Agenus is interested in identifying in-licensing candidates in oncology (including oncology supportive care), infectious diseases, and other niche indications. We are interested in clinical stage product candidates that would complement our existing business, including opportunities in which we could combine our Prophage Series vaccine candidates with other marketed or novel products. For further information please contact Investor Relations.

Out-Licensing

Agenus is interested in opportunities to advance its portfolio programs through partnerships. We are interested in exploring partnerships around our current portfolio including the Prophage Series, HerpV, and QS-21 Stimulon® adjuvant. For further information please contact Investor Relations.